Capacity Worries Fade for Biomanufacturing

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2003
Volume 27
Issue 7

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.

Recent Videos
Drug Digest: Strategic Partnerships
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content